We are live on ! Find out more
SCMP

Sucampo Pharmaceuticals, Inc.
SCMP

Delisted

SCMP was delisted on the 12th of February, 2018.

Back to rankings

167 hedge funds and large institutions have $287M invested in Sucampo Pharmaceuticals, Inc. in 2017 Q1 according to their latest regulatory filings, with 40 funds opening new positions, 57 increasing their positions, 47 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 30

32% more call options, than puts

Call options by funds: $1.48M | Put options by funds: $1.12M

21% more repeat investments, than reductions

Existing positions increased: 57 | Existing positions reduced: 47

1% more funds holding

Funds holding: 165 → 167 (+2)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

16% less capital invested

Capital invested by funds: $340M → $287M (-$52.9M)

Holders
167
Holders Change
+2
Holders Change %
+1.21%
% of All Funds
4.16%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
40
Increased
57
Reduced
47
Closed
30
Calls
$1.48M
Puts
$1.12M
Net Calls
+$359K
Net Calls Change
+$1.1M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$41.4M
2
KAM
Krensavage Asset Management
New York
+$10.9M
3
Millennium Management
Millennium Management
New York
+$6.03M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$5.55M
5
GCP
GSA Capital Partners
United Kingdom
+$2.88M

Top Sellers

Rank Fund Capital Flow
1
UOC
UBS O'Connor
Illinois
-$6.78M
2
Invesco
Invesco
Georgia
-$5.41M
3
NI
Numeric Investors
Massachusetts
-$5.02M
4
TA
Teachers Advisors
New York
-$4.86M
5
Renaissance Technologies
Renaissance Technologies
New York
-$4.04M
Name Holding Trade Value Shares
Change 		Change in
Stake
LPL Financial
176
LPL Financial
California
– -$776K -55,600 Closed
OA
177
Omega Advisors
New York
– -$678K -50,000 Closed
Walleye Trading
178
Walleye Trading
New York
– -$493K -36,400 Closed
AL
179
AJO LP
Pennsylvania
– -$443K -32,698 Closed
PA
180
Perceptive Advisors
New York
– -$416K -30,694 Closed
Nomura Holdings
181
Nomura Holdings
Japan
– -$340K -25,000 Closed
RG
182
Renaissance Group
Kentucky
– -$308K -22,723 Closed
BCM
183
Bayesian Capital Management
New York
– -$231K -17,059 Closed
Cambridge Investment Research Advisors
184
Cambridge Investment Research Advisors
Iowa
– -$188K -13,900 Closed
Balyasny Asset Management
185
Balyasny Asset Management
Illinois
– -$178K -13,173 Closed
TSS
186
Two Sigma Securities
New York
– -$147K -10,847 Closed
NIT
187
NumerixS Investment Technologies
British Columbia, Canada
– -$133K -9,801 Closed
CSS
188
Cubist Systematic Strategies
Connecticut
– -$115K -8,515 Closed
Group One Trading
189
Group One Trading
Illinois
– -$37.3K -3,216 Closed
DADC
190
D.A. Davidson & Co
Montana
– -$31K -2,340 Closed
PA
191
Parallel Advisors
California
– -$27K -2,000 Closed
TRCT
192
Tower Research Capital (TRC)
New York
– -$7K -574 Closed
Northwestern Mutual Wealth Management
193
Northwestern Mutual Wealth Management
Wisconsin
– -$3K -242 Closed
PIA
194
Piedmont Investment Advisors
North Carolina
– -$3.09K -228 Closed
APSP
195
Asset Planning Services (Pennsylvania)
Pennsylvania
– -$3K -200 Closed
GRP
196
Global Retirement Partners
California
– -$3K -195 Closed
PFBT
197
Parkside Financial Bank & Trust
Missouri
– +$267 +23 New
4 5 6 7
8

SCMP Hedge Fund Activity: Q1 2017 in Review

167 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Sucampo Pharmaceuticals, Inc. (SCMP) for Q1 2017, worth a combined $287M — down 16% from $340M a quarter earlier.

Buyers outnumbered sellers: 40 funds opened new SCMP positions and 30 closed out — a net gain of 10 holders — while 57 added to existing stakes and 47 trimmed.

The largest buyer was BlackRock, adding an estimated $41.4M. The largest seller was UBS O'Connor, exiting entirely with an estimated $6.78M sold.

  • 167 institutional investors held Sucampo Pharmaceuticals, Inc. (SCMP) as of Q1 2017, up from 165 in Q4 2016.
  • Funds reported $287M of Sucampo Pharmaceuticals, Inc. stock for Q1 2017, down 16% quarter-over-quarter.
  • 40 funds opened new Sucampo Pharmaceuticals, Inc. positions in Q1 2017 and 30 closed out, a net change of +10 holders.
  • The largest Sucampo Pharmaceuticals, Inc. buyer in Q1 2017 was BlackRock, an estimated $41.4M added.
  • The largest Sucampo Pharmaceuticals, Inc. seller in Q1 2017 was UBS O'Connor, an estimated $6.78M sold.

Based on aggregated 13F filings for Q1 2017.